Angioimmunoblastic lymphadenopathy: clinical spectrum of disease.

Abstract

The clinical features of 13 patients with angioimmunoblastic lymphadenopathy were analyzed to determine prognostic factors and response to therapy. Eleven patients presented with sudden onset of fever, weight loss, generalized lymphadenopathy, and hepatosplenomegaly. Laboratory features included autoimmune hemolytic anemia and polyclonal hypergammaglobulinemia. Pulmonary involvement was seen in six cases and skin rash in four. Two patients had localized lymphadenopathy without systemic symptoms. Both are alive at 5.5 and 2.5 years, respectively, after diagnosis, although the latter patient has required intermittent prednisone for recurrent lymphadenopathy. An additional patient is alive on treatment for months following diagnosis. The remaining ten have died, nine of sepsis and one of cerebral hemorrhage. The immunosuppression and myelosuppression of combination chemotherapy may have hastened their deaths. An individualized, conservative treatment approach is recommended.

• Authors: P K Schauer, D J Straus, C M Bagley Jr, R H Rudolph, J D McCracken, J Huff, H Glucksburg, D E Bauermeister, B D Clarkson
• Journal: Cancer (Cancer) Vol. 48 Issue 11 Pg. 2493-8 (Dec 01 1981) ISSN: 0008-543X [Print] United States
• PMID: 7296497 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents

Topics

• Aged
• Antineoplastic Agents (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Immunoblastic Lymphadenopathy (diagnosis, drug therapy)
• Male
• Middle Aged
• Prognosis